Leznoda

Brinzolamide, the active ingredient in Leznoda, is a carbonic anhydrase inhibitor presented as eye drops for ocular (topical) use. It helps lower intra‑ocular pressure in patients with primary open‑angle glaucoma or ocular hypertension. Leznoda also contains brimonidine tartrate, an alpha‑2 adrenergic agonist that further reduces eye pressure. GNH USA supplies Leznoda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leznoda is indicated for conditions affecting intra‑ocular pressure within the glaucoma disease family. - Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: reduces eye pressure to prevent progression to glaucoma. - Secondary open‑angle glaucoma: assists in controlling elevated pressure when other therapies are insufficient.

Leznoda may cause ocular and systemic reactions.

Common Side Effects: - Transient eye irritation or burning on instillation. - Blurred vision shortly after dosing. - Dry eye sensation. - Mild headache.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Persistent ocular inflammation or uveitis. - Significant reduction in heart rate or blood pressure. - Acute angle‑closure glaucoma precipitated by improper use.

Before using Leznoda, consider the following precautions. - Monitor IOP: regular intra‑ocular pressure measurements are essential to assess efficacy. - Assess ocular surface: discontinue if severe irritation or allergic signs develop. - Systemic conditions: use caution in patients with severe cardiovascular disease due to possible brimonidine effects. - Concomitant eye medications: avoid simultaneous use with other topical agents unless directed by a clinician. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at room temperature: keep in the original container, protect from light and moisture.

Leznoda can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive reduction in aqueous humor may cause excessive IOP lowering. - Monoamine oxidase inhibitors: potential for exaggerated brimonidine‑related hypotension.

Moderate Interactions (Monitor Closely): - Other intra‑ocular pressure‑lowering eye drops (e.g., beta‑blockers, prostaglandin analogues): monitor for over‑lowering of IOP. - Topical non‑steroidal anti‑inflammatory drugs: may increase ocular irritation. - Antihypertensive agents: observe blood pressure for additive hypotensive effect.